ArticleThe European respiratory journal2020
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.
5 registry-linked trialsAbstract read
In one paragraph
Article in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,943 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,943citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization
Impact of COVID-19 on the Benefit of Cardiac Rehabilitation
Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19
Outcomes of Diabetes In Hospitalized COVID-19 Patients At Assiut University Hospital
A Randomized, Placebo-controlled, Double-blind, Monocenter, Phase II Trial to Assess the Efficacy of Calcium Dobesilate (CaD) vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.
Who cites it
1,943 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19.Advances in respiratory medicine · 2025Pooled it
- COVID-19 vaccine acceptance and its association with knowledge and attitude among patients with chronic diseases in Ethiopia.Human vaccines & immunotherapeutics · 2024Pooled it
- A pandemic of delirium: an updated systematic review and meta-analysis of occurrence of delirium in older adults with COVID-19.European geriatric medicine · 2024Pooled it
- Multimorbidity and frailty are associated with poorer SARS-CoV-2-related outcomes: systematic review of population-based studies.Aging clinical and experimental research · 2024Pooled it
- Tailored vs. General COVID-19 prevention for adults with mental disabilities residing in group homes: a randomized controlled effectiveness-implementation trial.BMC public health · 2024Trial
- Outcomes of the Dulce Digital-COVID Aware (DD-CA) discharge texting platform for US/Mexico border Hispanic individuals with diabetes.Diabetes research and clinical practice · 2024Trial
- Article
- Environmental Exposure to Endocrine-Disrupting Chemicals and SARS-CoV-2 Infection History Among Blood Donors.Life (Basel, Switzerland) · 2026Article
- Article
- Temporal Evolution of the Impact of CKD on COVID-19 Outcomes : A 5-Year Nationwide Analysis.Kidney360 · 2026Article
- Age and comorbidity in COVID-19 mortality: a retrospective cohort study using multivariable regression and interaction analyses.BMC infectious diseases · 2026Article
- Impact of Risk Factor Combinations on Severe COVID-19 Outcomes Among Outpatients.Infectious diseases and therapy · 2026Article
- Plasma multi-omics profiling unravels molecular alterations and biomarker panels during recovery from severe coronavirus disease 2019: a pilot study.BMC infectious diseases · 2026Article
- Article
- Clinical Characteristics and Factors Associated With Critical Illness and Mortality in Patients Hospitalized With COVID-19: A Retrospective Cohort Study in Taiwan.Journal of acute medicine · 2026Article
- Early chest x-ray severity assessed by the MBrixia score is associated with mortality in hospitalized patients with COVID-19 pneumonia.Scientific reports · 2026Article
- Article
- Effect of COVID-19 vaccination and SARS-CoV-2 infection status on mortality risk in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.Respiratory research · 2026Article
- Article
- Heterogeneous immune recovery after viral response through a dynamical model of feedback-driven persistence and clearance.Frontiers in immunology · 2026Article
1,883 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
48 authors.
Wei-Jie GuanState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Wen-Hua LiangDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yi ZhaoDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Heng-Rui LiangDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zi-Sheng ChenDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yi-Min LiDept of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xiao-Qing LiuDept of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ru-Chong ChenState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Chun-Li TangState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Tao WangState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Chun-Quan OuState Key Laboratory of Organ Failure Research, Dept of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Li LiState Key Laboratory of Organ Failure Research, Dept of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Ping-Yan ChenState Key Laboratory of Organ Failure Research, Dept of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Ling SangDept of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wei WangDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jian-Fu LiDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Cai-Chen LiDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Li-Min OuDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Bo ChengDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shan XiongDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zheng-Yi NiWuhan Jin-yintan Hospital, Wuhan, China.
Jie XiangWuhan Jin-yintan Hospital, Wuhan, China.
Yu HuUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lei LiuShenzhen Third People's Hospital, Shenzhen, China.
Hong ShanThe Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Chun-Liang LeiGuangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Yi-Xiang PengThe Central Hospital of Wuhan, Wuhan, China.
Li WeiWuhan No. 1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China.
Yong LiuChengdu Public Health Clinical Medical Center, Chengdu, China.
Ya-Hua HuHuangshi Central Hospital of Edong Healthcare Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Peng PengWuhan Pulmonary Hospital, Wuhan, China.
Jian-Ming WangTianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
Ji-Yang LiuThe First Hospital of Changsha, Changsha, China.
Zhong ChenThe Third People's Hospital of Hainan Province, Sanya, China.
Gang LiHuanggang Central Hospital, Huanggang, China.
Zhi-Jian ZhengWenling First People's Hospital, Wenling, China.
Shao-Qin QiuThe Third People's Hospital of Yichang, Yichang, China.
Jie LuoAffiliated Taihe Hospital of Hubei University of Medicine, Shiyan, China.
Chang-Jiang YeXiantao First People's Hospital, Xiantao, China.
Shao-Yong ZhuThe People's Hospital of Huangpi District, Wuhan, China.
Lin-Ling ChengState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Feng YeState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Shi-Yue LiState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jin-Ping ZhengState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Nuo-Fu ZhangState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Nan-Shan ZhongState Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jian-Xing HeDept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China drjianxing.he@gmail.com nanshan@vip.163.com.
China Medical Treatment Expert Group for COVID-19
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.
objectiveTo evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.
methodsWe analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.
resultsThe mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424-5.048)), diabetes (1.59 (1.03-2.45)), hypertension (1.58 (1.07-2.32)) and malignancy (3.50 (1.60-7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16-2.77) among patients with at least one comorbidity and 2.59 (1.61-4.17) among patients with two or more comorbidities.
conclusionAmong laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.
Indexed as
BetacoronavirusAdultChinaComorbidityCoronavirus InfectionsCOVID-19FemaleHumansMaleMiddle AgedPandemicsPneumonia, ViralPrognosisRisk FactorsSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT04365582ClinicalTrials.gov
NCT04513964ClinicalTrials.gov
NCT04542213ClinicalTrials.gov
NCT05083013ClinicalTrials.gov
NCT05305508ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.